

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lieven Meerpoel

Serial No. : Not Assigned

Art Unit: Not Assigned

Filed : Herewith

Examiner: Not Assigned

For : N-ARYL PIPERIDINE SUBSTITUTED  
BIPHENYLCARBOXAMIDES AS INHIBITORS OF  
APOLIPOPROTEIN B SECRETION

Commissioner for Patents  
Alexandria, VA. 22313

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application

EXPRESS MAIL LABEL NO. EV 138 489 201 US  
DOCKET NO. JAB 1742USPCT

(other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance

EXPRESS MAIL LABEL NO. EV 138 489 201 US  
DOCKET NO. JAB 1742USPCT

under \$1.311 but before the payment of the Issue Fee.  
Applicant(s) hereby petition(s) for consideration of this  
Information Disclosure Statement. Included are: Statement in  
Accordance with \$1.97(e) as set forth below and the fee of  
\$180.00 as set forth in \$1.17(p).

☒ Copies of each of the references listed on the  
attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-  
1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references  
[list as appropriate], and the likelihood that  
these references are available to the Examiner,  
copies are not enclosed herewith.

☐ If any of the foregoing publications are not  
available to the Examiner, Applicant will  
endeavor to supply copies at the Examiner's  
request.

☒ There are no listed references which are not in the  
English language.

☐ The relevance of those listed references which are  
not in the English language is as follows:

☒ Attached are copies of search report(s) from  
corresponding patent application(s), which are listed on the  
attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB1742USPCT/MBZ. This form is submitted in triplicate.

Respectfully submitted,



Matthew B. Zisk,  
Reg. No. 45,257  
Attorney for Applicants

Johnson & Johnson  
One Johnson & Johnson Plaza  
New Brunswick, NJ 08933-7003  
(732) 524-1287  
DATED: February 8, 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

<b>Application Number</b>	Not yet Assigned
<b>Filing Date</b>	Herewith
<b>First Named Inventor</b>	Lieven Meerpoel
<b>Group Art Unit</b>	Not yet Assigned
<b>Examiner Name</b>	Not yet Assigned
<b>Attorney Docket Number</b>	JAB 1742USPCT

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
		WO	00/32582	A1	Glaxo Group Ltd.	06/08/2000		
		WO	01/96327	A1	Glaxo Group Ltd.	12/20/2001		
		WO	01/97810	A2	Glaxo Group Ltd.	12/27/2001		
		WO	02/20501	A2	Janssen Pharmaceutica, N.V.	03/14/2002		
		WO	02/081460	A1	Janssen Pharmaceutica, N.V.	10/17/2002		

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		SHARP D. et al., "Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia." Nature, 1993, page 65-69, Vol. 365.	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313-1450..

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 22313-1450.

Page 1 of 1

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
--------------------	--	-----------------	--